

Enantioselective Syntheses of 2-Alkyl- and 2,6-Dialkylpiperidine Alkaloids: Preparations of the Hydrochlorides of (–)-Coniine, (–)-Solenopsin A, and (–)-Dihydropinidine


Timothy J. Wilkinson, Nathan W. Stehle, and Peter Beak*

Department of Chemistry, University of Illinois at Urbana–Champaign,
Urbana, Illinois 61801

beak@scs.uiuc.edu

Received November 17, 1999

ABSTRACT



Sequences of lithiation–substitution, enantioselective hydrogenation, and diastereoselective lithiation–substitution provide efficient highly enantioselective syntheses of 2-substituted and *cis* and *trans* 2,6-disubstituted piperidines. The methodology is demonstrated by syntheses of (–)-coniine, (–)-solenopsin A, and (–)-dihydropinidine as their hydrochlorides.

Direct elaborations of *N*-Boc amines by lithiation–substitution reactions offer opportunities for convenient and efficient syntheses of alkaloid ring systems. The piperidine family, which includes many compounds with useful pharmacological properties, has been a target of particular interest.¹ Enantioselective syntheses of members of this family, (–)-coniine² (**1**), (–)-solenopsin A^{2a,b,3} (**2**) and (–)-dihydro-

pinidine^{2cd,4} (**3**) have been the focus of many studies.

We wish to report that lithiation–substitution and asymmetric hydrogenation can be used as key steps in convenient and efficient syntheses of highly enantioenriched 2-substituted and *cis* and *trans* 2,6-disubstituted piperidines from commercially available materials. This methodology is demonstrated for preparations of the hydrochlorides of the

(1) For a review, see Bailey, P. D.; Millwood, P. A.; Smith, P. D. *Chem. Comm.* **1998**, 633 and references therein.


(2) (a) Oppolzer, W.; Bochet, C.; Christian, G.; Merified, E. *Tetrahedron Lett.* **1994**, 35, 7015. (b) Oppolzer, W. *Pure Appl. Chem.* **1994**, 66, 2127. (c) Katritzky, A.; Qiu, G.; Yang, B.; Steel, P. *J. Org. Chem.* **1998**, 63, 6699. (d) Guerrier, Luc.; Royer, J.; Grierson, D.; Husson, H. *J. Am. Chem. Soc.* **1983**, 105, 7754. (e) Weymann, M.; Pfrenkle, W.; Schollmeyer, D.; Kunz, H. *Synthesis* **1997**, 10, 1151. (f) Pandey, G.; Das, P. *Tetrahedron Lett.* **1997**, 38, 9073. (g) Moody, C.; Lightfoot, A.; Gallagher, P. *J. Org. Chem.* **1997**, 62, 746. (h) Kim, Y.; Choi, J. *Tetrahedron Lett.* **1996**, 37, 5543. (i) Amat, M.; Llor, N.; Bosch, J. *Tetrahedron Lett.* **1994**, 35, 2223. (j) Enders, D.; Tiebes, J. *Liebigs Ann. Chem.* **1993**, 2, 173. (k) Ito, M.; Maeda, M.; Kibayashi, C. *Tetrahedron Lett.* **1992**, 33, 3765. (l) Higashiyama, K.; Naakahata, K.; Takahashi, H. *Heterocycles* **1992**, 33, 17. (m) Lathbury, D.; Gallagher, T. *J. Chem. Soc., Chem. Comm.* **1986**, 2, 114. (n) Sanchez-Sancho, F.; Herradon, B. *Tetrahedron: Asymmetry* **1998**, 9, 1951.

(o) Nazabadioko, S.; Perez, R.; Brieva, R.; Gotor, V. *Tetrahedron: Asymmetry* **1998**, 9, 1597. (p) Al-awar, R.; Joseph, S.; Comins, D. *J. Org. Chem.* **1993**, 58, 7732. (q) Kiguchi, T.; Nakazono, Y.; Kotera, S.; Ninomiya, I.; Naito, T. *Heterocycles* **1990**, 31, 1525.


(3) (a) Reding, M. T.; Buchwald, S. L. *J. Org. Chem.* **1998**, 63, 6344. (b) Solladie, G.; Huser, N. *Recl. Trav. Chim. Pays-Bas* **1995**, 114, 153. (c) Jefford, C. W.; Wang, J. *Tetrahedron Lett.* **1993**, 34, 2911. (d) Ukaji, Y.; Watai, T.; Sumi, T.; Fujisawa, T. *Chem. Lett.* **1991**, 9, 1555. (e) Amat, M.; Hidalgo, J.; Llor, N.; Bosch, J. *Tetrahedron: Asymmetry* **1998**, 9, 2419. (f) Comins, D.; Benjelloun, N. *Tetrahedron Lett.* **1994**, 35, 829. (g) Leclercq, S.; Daloze, D.; Braekman, J.-C. *Org. Prep. Proced. Int.* **1996**, 28, 499.

(4) (a) Hill, R. K.; Yuri, T. *Tetrahedron* **1977**, 33, 1569. (b) Yamauchi, T.; Takahashi, H.; Higashiyama, K. *Chem. Pharm. Bull.* **1998**, 46, 384. (c) Lu, Z.; Zhou, W. *J. Chem. Soc., Perkin Trans. 1* **1993**, 5, 593. (d) Theodorakis, E.; Royer, J.; Husson, H. *Synth. Comm.* **1991**, 21, 521.

alkaloids **1–3** from *N*-Boc-3-methoxy piperidine and *N*-Boc- δ -valerolactam via (*S*)-*N*-Boc-pipecolic acid.



Asymmetry is introduced into the piperidine ring by the enantioselective hydrogenation of 2-carboxy-*N*-Boc-1,4,5,6-tetrahydropyridine (**4**) with the Noyori catalyst⁵ (*S*)-BINAP-RuCl₂ to yield (*S*)-*N*-Boc-pipecolic acid (**5**) in high enantioenrichment after one recrystallization as shown in Scheme 1. Prior to recrystallization, **5** is obtained in 95% yield with



an er of 98:2 as shown in Table 1. The table also shows that reductions of the *N*-*tert*-butyl amide, the *N*-(3,5-dimethyl) phenyl amide, the *N*,*N*-diethyl amide, and the methyl ester corresponding to **4** with (*S*)-BINAP-RuCl₂ provided the


Table 1. Reduction of **4** and Derivatives with (*S*)-BINAP-RuCl₂

Y	yield (%)	er
OH	95	98:2
NH- <i>t</i> -Bu	99	98:2
NH-3,5-Me ₂ C ₆ H ₃	78	96:4
N(C ₂ H ₅) ₂	83	87:13
OCH ₃	66	73:27

expected enantioenriched reduction products in 99%, 78%, 83%, and 66% yields with ers of 98:2, 96:4, 87:13, and 73:27, respectively. Reductions of **4** with (*S*)-BINAP-Rh(I), (*R*,*R*)-DIPAMP-Rh(I) gave the racemic acid, while (*R*,*R*)-Me-DuPhos-Rh(I) afforded the product with an er of 71:29.⁶ Reduction of 2-carboxymethyl-*N*-phenoxy carbonyl 1,4,5,6-

tetrahydropyridine with (*R*)-BINAP-RuCl₂, as reported by Foti and Commins, gives an (*S*)-configured product in 52% yield with an er of 90:10.⁷ It is interesting that their ester, which differs from the methyl ester of **4** only by a *tert*-butyl group vs a phenyl group on the *N*-carboxy function, gives a product that has the same configuration as we observe, although they use the catalyst of the opposite configuration.^{7,8} Changes in the facial selectivity in reductions with chiral Ru(II) complexes at different pressures are known, although changes to this degree are unusual.^{5b}

The precursor to (*S*)-*N*-Boc-pipecolic acid (**5**), 2-carboxy-*N*-Boc-1,4,5,6-tetrahydropyridine (**4**), was prepared by either of two methods as shown in Scheme 2. Following our



previous report, 3-hydroxypiperidine hydrochloride (**6**) was reacted with (Boc)₂O to afford **7** in 83% yield.⁹ Treatment of **7** with sodium hydride and iodomethane gave **8** in 89% yield. The reaction of **8** with 2 equiv of *s*-BuLi/TMEDA (−78 °C, 5 h), followed by the addition of carbon dioxide, afforded **4** in 80% yield.⁹ In an alternative sequence, δ -valerolactam (**9**) was reacted with (Boc)₂O and DMAP in acetonitrile to afford **10** in 79% yield. Reduction with DIBALH gave lactamol **11**, which was dehydrated without purification with *p*-TsOH in toluene to provide the enecarbamate **12** in 86% yield from **10** following the procedure of Dieter.¹⁰ When **12** was reacted with *s*-BuLi/TMEDA, under conditions similar to those used for the conversion of **8** to **4**, low yields of **4** were obtained. A yield of 52% of **4** was

(5) (a) Noyori, R.; Ohkuma, T.; Kitamura, M. *J. Am. Chem. Soc.* **1987**, *109*, 5856. See also (b) Noyori, R. *Asymmetric Catalysis In Organic Synthesis*; Wiley-Interscience: New York, 1994; Chapter 2. (c) Saburi, M.; Shao, L.; Sakurai, T.; Uchida, Y. *Tetrahedron Lett.* **1992**, *33*, 7877.

(6) (a) Miyashita, A.; Yasuda, A.; Takaya, H.; Toriumi, K.; Ito, T.; Souichi, T.; Noyori, R. *J. Am. Chem. Soc.* **1980**, *102*, 7932. (b) Miyashita, A.; Takaya, H.; Souichi, T.; Noyori, R. *Tetrahedron* **1984**, *40*, 1245. (c) Ohta, T.; Takaya, H.; Kitamura, M.; Nagai, K.; Noyori, R. *J. Org. Chem.* **1987**, *52*, 3174. (d) Mashima, K.; Kusano, K.; Ohta, T.; Noyori, R.; Takaya, H. *J. Chem. Soc., Chem. Commun.* **1989**, 1209. (e) Kawano, H.; Ikariya, T.; Ishii, X.; Saburi, M.; Uchida, Y.; Kumobayashi, H. *J. Chem. Soc., Perkin Trans 1* **1989**, 1571. (f) Saburi, M.; Shao, L.; Sakurai, T.; Uchida, Y. *Tetrahedron Lett.* **1992**, *33*, 7877. (g) Vineyard, B. D.; Knowles, W. J.; Sabacky, M. J.; Bachman, G. L.; Weinkauff, D. J. *J. Am. Chem. Soc.* **1977**,

99, 5946–5952. (h) Knowles, W. S. *Acc. Chem. Res.* **1983**, *16*, 106. (i) Burk, M. J.; Feaster, J. E.; Nugent, W. A.; Harlow, R. L. *J. Am. Chem. Soc.* **1993**, *115*, 10125–10138. (j) Burk, M. J.; Wang, X. M.; Lee, J. R. *J. Am. Chem. Soc.* **1996**, *118*, 5142–5143. (k) Ojima, I.; Kogure, T.; Yoda, N. *J. Org. Chem.* **1980**, *45*, 4728–4739.

(7) Foti, C. J.; Comins, D. L. *J. Org. Chem.* **1995**, *60*, 2656–2657.

(8) For mechanistic analysis of related reactions, see (a) Chan, A. S. C.; Pluth, J. J.; Halpern, J. *J. Am. Chem. Soc.* **1980**, *102*, 5952. (b) Chua, P. S.; Roberts, N. K.; Bosnich, B.; Okrasinski, S. J.; Halpern, J. *J. Chem. Soc., Chem. Commun.* **1981**, 1278. (c) Landis, C. L.; Halpern, J. *J. Am. Chem. Soc.* **1987**, *109*, 1746–1754. (d) Ashby, M. T.; Halpern, J. *J. Am. Chem. Soc.* **1991**, *113*, 589–594.

(9) Beak, P.; Lee, W. K. *J. Org. Chem.* **1993**, *58*, 1109.


(10) Dieter, R. K.; Sharma, R. R. *J. Org. Chem.* **1996**, *61*, 4180.

achieved in the reaction of **12** with *n*-BuLi/TMEDA (−65 to −30 °C, 30 min), followed by treatment with carbon dioxide. The crude product from this reaction contained approximately 25% 5-nonanone, based on its ¹H NMR spectrum, indicating that nucleophilic additions of *n*-BuLi to carbonyl groups can be competitive with the lithiation of **12** by *n*-BuLi.

The formation of **4** from **12** is considered to occur by metalation at the vinyl position, followed by reaction of the vinyl lithium intermediate with carbon dioxide. A reasonable pathway for the conversion of **8** to **4** is initial lithiation adjacent to nitrogen followed by elimination of methoxide to afford **12**.⁹ However, the lower yield of **4** from the direct reaction of **12** with *s*-BuLi (vide supra) and the failure of **12** to give increased yields of **4** in the presence of lithium methoxide suggests that these reactions have similar but different pathways.

The enantioselective formation of **5** combined with our previous studies of diastereoselectivities in lithiation–substitutions of substituted *N*-Boc-piperidines provides a basis for convenient syntheses of highly enantioenriched 2-substituted and 2,6-disubstituted piperidine alkaloids. The following syntheses are based on previous syntheses.⁹


(–)-Coniine Hydrochloride (1·HCl). Reduction of **5** with BH₃·THF provided alcohol **13** in 97% yield. The alcohol **13** was oxidized by the Katzenellenbogen modification of the Swern oxidation to provide aldehyde **14**, which was immediately reacted with the ylide of (ethyl)triphenylphosphonium bromide to afford **15** in 79% overall yield based on **13**.^{2no,5,11} Catalytic hydrogenation of **15** with 5% Pd/C provided **16** in 93% yield as shown in Scheme 3. Treatment



of **16** with HCl–methanol afforded (–)-coniine hydrochloride (**1·HCl**) in 98% yield. The overall yield from **5** is 70%. Mp 219–220 °C (lit.^{2c} 218–221 °C); [α]_D²⁰ −6.5° (*c* = 1.0, EtOH) (lit.^{2c} [α]_D²⁰ −7.3° (*c* 1.0, MeOH)).


(–)-Solenopsin A Hydrochloride (2·HCl). Reaction of aldehyde **14** with the ylide of (decyl)triphenylphosphonium iodide afforded **17** in 79% yield.¹² Hydrogenation with 10%

Pd/C then gave **18** in 95% yield. Lithiation of **18** with *s*-BuLi/TMEDA followed by treatment with dimethyl sulfate provided **19** in 80% yield as shown in Scheme 4.^{3a,f,5}



Deprotection with HCl–MeOH gave (–)-solenopsin A hydrochloride (**2·HCl**) in 97% yield. The overall yield from **5** is 56%. Mp 148–149 °C (lit.^{3c} 147–150 °C); [α]_D²⁰ −8.2 (*c* 0.5, CHCl₃) (lit.^{3c} [α]_D²⁰ −7.7 (*c* 0.51, CHCl₃)).

(–)-Dihydropinidine Hydrochloride (3·HCl). Treatment of **16** with *s*-BuLi/TMEDA followed by DMF afforded a 10:90 *cis*–*trans* mixture of aldehydes, based on the ¹H NMR spectrum of the crude product. The aldehyde mixture was isomerized with silica gel to provide an 83:17 *cis*–*trans* mixture from which **20** was obtained in 74% yield by flash chromatography.^{5,13} Reduction of **20** with sodium borohydride gave **21** in 85% yield. Deoxygenation of **21** was accomplished in two steps by a Barton deoxygenation.¹⁴ Alcohol **21** was converted to the thionocarbonate **22** in 88% yield by the reaction with phenylchlorothionoformate/DMAP. Reduction with tributyltin hydride/AIBN followed by reflux with TBAF provided **23** in 48% yield. Deprotection of **23** with HCl–methanol afforded (–)-dihydropinidine hydrochloride (**3·HCl**) in 90% yield as shown in Scheme 5. The




(11) Reed, P. E.; Katzenellenbogen, J. A., *J. Org. Chem.* **1991**, *56*, 2624.

(12) Chasin, D. G.; Perkins, E. G. *Chem. Phys. Lipids* **1971**, *6*, 8.

(13) A related isomerization was reported with K₂CO₃–methanol: Kotsuki, H.; Kusumi, M. I.; Ushio, Y.; Ochi, M. *Tetrahedron Lett.* **1991**, *32*, 4159.

Scheme 6



overall yield from **5** was 17%. Mp 242–243 °C (lit.^{4b} 234 °C); $[\alpha]_D^{20} -13.3^\circ$ (*c* 1.0, EtOH) (lit.^{4b} $[\alpha]_D^{20} -12.74^\circ$ (*c* 0.47 EtOH)).

The flexibility of this methodology, in accessing both *cis* and *trans* 2,6-disubstituted piperidines, lies in the structure and reactivity of the intermediate lithiated *N*-Boc piperidines.⁹ Lithiations of **16** and **18**, in which the 2-substituent is axial

(14) Robins, M. J.; Wilson, J. S.; Hanssle, F. *J. Am. Chem. Soc.* **1983**, *105*, 4059.

(15) Hoffmann, R. W. *Chem. Rev.* **1989**, *89*, 1841.

as a result of A_{1,3} strain, provides **24** and **25** in which the lithium is equatorial.^{9,15} Subsequent methylation of **24** occurs with retention of configuration to afford **19**. Similarly, **16** provides **26** via **25**. In this case, however, A_{1,3} strain provides a driving force for equilibration to afford **20**.^{9,15} The reactions are outlined in Scheme 6. The stereochemical outcomes of the reactions leading to *cis* or *trans* 2,6-disubstituted piperidines are consistent with principles that should be applicable to related systems.

Because both enantiomers of the catalyst are commercially available, both (*S*)- and (*R*)-*N*-Boc-pipecolic acid can be prepared with high enantiointegrity.⁵ The diastereoselectivities of subsequent lithiation–substitution and equilibration allows a high degree of stereochemical control. Although the present syntheses afford alkyl-substituted piperidines, this approach can provide highly enantioenriched 2-substituted and *cis* and *trans* 2,6-disubstituted piperidine rings with many functionalities and with any desired absolute configuration.

Acknowledgment. We are grateful to the National Institutes of Health (GM-18874) and the National Science Foundation (NSF-19422) for support of this work. Tim Wilkinson is grateful to Wheaton College for sabbatical support.

Supporting Information Available: Full experimental details for the syntheses reported are provided. This material is available free of charge via the Internet at <http://pubs.acs.org>

OL9912534